481 related articles for article (PubMed ID: 24779345)
1. Immunocompetent murine models for the study of glioblastoma immunotherapy.
Oh T; Fakurnejad S; Sayegh ET; Clark AJ; Ivan ME; Sun MZ; Safaee M; Bloch O; James CD; Parsa AT
J Transl Med; 2014 Apr; 12():107. PubMed ID: 24779345
[TBL] [Abstract][Full Text] [Related]
2. Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes.
Letchuman V; Ampie L; Shah AH; Brown DA; Heiss JD; Chittiboina P
Neurosurg Focus; 2022 Feb; 52(2):E5. PubMed ID: 35104794
[TBL] [Abstract][Full Text] [Related]
3. A syngeneic mouse glioma model for study of glioblastoma therapy.
Weiner NE; Pyles RB; Chalk CL; Balko MG; Miller MA; Dyer CA; Warnick RE; Parysek LM
J Neuropathol Exp Neurol; 1999 Jan; 58(1):54-60. PubMed ID: 10068314
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development.
Majc B; Novak M; Kopitar-Jerala N; Jewett A; Breznik B
Cells; 2021 Jan; 10(2):. PubMed ID: 33572835
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.
Belmans J; Van Woensel M; Creyns B; Dejaegher J; Bullens DM; Van Gool SW
Sci Rep; 2017 Oct; 7(1):13902. PubMed ID: 29066810
[TBL] [Abstract][Full Text] [Related]
6. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
7. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
Chonan M; Saito R; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Watanabe M; Kikuchi T; Ishii N; Tominaga T
Neuro Oncol; 2015 Nov; 17(11):1453-62. PubMed ID: 26008605
[TBL] [Abstract][Full Text] [Related]
8. Technical choices significantly alter the adaptive immune response against immunocompetent murine gliomas in a model-dependent manner.
Noffsinger B; Witter A; Sheybani N; Xiao A; Manigat L; Zhong Q; Taori S; Harris T; Bullock T; Price R; Purow B
J Neurooncol; 2021 Sep; 154(2):145-157. PubMed ID: 34432197
[TBL] [Abstract][Full Text] [Related]
9. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
10. Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma.
Miller J; Eisele G; Tabatabai G; Aulwurm S; von Kürthy G; Stitz L; Roth P; Weller M
J Neurosurg; 2010 Aug; 113(2):280-5. PubMed ID: 19961309
[TBL] [Abstract][Full Text] [Related]
11. The network of immunosuppressive pathways in glioblastoma.
Mangani D; Weller M; Roth P
Biochem Pharmacol; 2017 Apr; 130():1-9. PubMed ID: 28017775
[TBL] [Abstract][Full Text] [Related]
12. Challenges in clinical design of immunotherapy trials for malignant glioma.
Rolle CE; Sengupta S; Lesniak MS
Neurosurg Clin N Am; 2010 Jan; 21(1):201-14. PubMed ID: 19944979
[TBL] [Abstract][Full Text] [Related]
13. Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells.
Clark AJ; Safaee M; Oh T; Ivan ME; Parimi V; Hashizume R; Ozawa T; James CD; Bloch O; Parsa AT
J Transl Med; 2014 Dec; 12():345. PubMed ID: 25464980
[TBL] [Abstract][Full Text] [Related]
14. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
[TBL] [Abstract][Full Text] [Related]
15. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.
Hellums EK; Markert JM; Parker JN; He B; Perbal B; Roizman B; Whitley RJ; Langford CP; Bharara S; Gillespie GY
Neuro Oncol; 2005 Jul; 7(3):213-24. PubMed ID: 16053696
[TBL] [Abstract][Full Text] [Related]
16. Advances in immunotherapy for the treatment of glioblastoma.
Tivnan A; Heilinger T; Lavelle EC; Prehn JH
J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
[TBL] [Abstract][Full Text] [Related]
17. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
18. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.
Reardon DA; Wucherpfennig KW; Freeman G; Wu CJ; Chiocca EA; Wen PY; Curry WT; Mitchell DA; Fecci PE; Sampson JH; Dranoff G
Expert Rev Vaccines; 2013 Jun; 12(6):597-615. PubMed ID: 23750791
[TBL] [Abstract][Full Text] [Related]
19. Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells.
Xu M; Yao Y; Hua W; Wu Z; Zhong P; Mao Y; Zhou L; Luo F; Chu Y
J Neurooncol; 2014 Feb; 116(3):497-504. PubMed ID: 24398615
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for glioma: promises and challenges.
Han SJ; Zygourakis C; Lim M; Parsa AT
Neurosurg Clin N Am; 2012 Jul; 23(3):357-70. PubMed ID: 22748649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]